Internal Medicine, Medical Oncology · New York, NY
NPI
1215226824
Since 2011
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
325 W 15th St
New York, NY, 10011
Phone (212) 604-6017
Groups this clinician bills Medicare through
Medicare paid, 2024
$45K
430 services
Medicare patients, 2024
135
Average age 75
Drug cost, 2024
$4.2M
611 prescriptions
Company payments, 2025
$16K
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Nicholas C Rohs was code 99215 (office e&m - established), 279 times for 78 patients. In total Nicholas C Rohs billed 430 services in 10 codes, and Medicare paid $45K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-07-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 279 | 78 | $113.63 | $32K |
| 99214 Office E&M - Established | Office | 112 | 69 | $78.51 | $8,793 |
| 99205 Office E&M - New | Office | 17 | 17 | $136.81 | $2,326 |
By year: 2022 $74K for 635 services; 2023 $55K for 500 services; 2024 $45K for 430 services.
Medicare prescription drug claims, 2024
In 2024, the drug Nicholas C Rohs prescribed most often to Medicare patients was Tagrisso (Osimertinib Mesylate), with 62 prescriptions and refills. In total Nicholas C Rohs wrote 611 Medicare prescriptions that cost $4.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tagrisso Osimertinib Mesylate | 62 | 62 | Under 11 | $1.0M |
| Dexamethasone Generic | 47 | 47 | 24 | $342 |
| Alecensa Alectinib Hcl | 47 | 47 | Under 11 | $839K |
| Ondansetron Odt Ondansetron | 45 | 45 | 24 | $324 |
| Oxycodone Hcl Generic | 36 | 36 | 12 | $279 |
| Tafinlar Dabrafenib Mesylate | 34 | 34 | Under 11 | $348K |
| Mekinist Trametinib Dimethyl Sulfoxide | 34 | 34 | Under 11 | $377K |
| Folic Acid Generic | 32 | 34 | Under 11 | $82.43 |
| Tepmetko Tepotinib Hcl | 19 | 22 | Under 11 | $435K |
| Prednisone Generic | 17 | 21 | Under 11 | $42.71 |
| Eliquis Apixaban | 17 | 17 | Under 11 | $9,627 |
| Xarelto Rivaroxaban | 16 | 18 | Under 11 | $9,898 |
| Imatinib Mesylate Generic | 14 | 14 | Under 11 | $2,254 |
| Gilotrif Afatinib Dimaleate | 13 | 13 | Under 11 | $133K |
| Erlotinib Hcl Generic | 12 | 12 | Under 11 | $16K |
Brand drugs: 299 claims; generic drugs: 312 claims; opioid claims: 57.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Nicholas C Rohs $16K ($16K in general payments such as food, travel and fees) from 4 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $8,146.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.